Nancy Ann Oberheim Bush
A5091257992- Glioma Diagnosis and Treatment
- Meningioma and schwannoma management
- Brain Metastases and Treatment
- Medical Imaging and Pathology Studies
- Radiomics and Machine Learning in Medical Imaging
- Cancer Genomics and Diagnostics
- Cancer, Hypoxia, and Metabolism
- Neuroblastoma Research and Treatments
- Advanced MRI Techniques and Applications
- Neurofibromatosis and Schwannoma Cases
- CAR-T cell therapy research
- MRI in cancer diagnosis
- Pituitary Gland Disorders and Treatments
- Medical Imaging Techniques and Applications
- Cancer Immunotherapy and Biomarkers
- Advanced NMR Techniques and Applications
- Adrenal and Paraganglionic Tumors
- Cancer Research and Treatments
- Epigenetics and DNA Methylation
- Neuroscience and Neuropharmacology Research
- Cancer-related cognitive impairment studies
- Cancer Treatment and Pharmacology
- Radiopharmaceutical Chemistry and Applications
- Biomedical Ethics and Regulation
- Neuroinflammation and Neurodegeneration Mechanisms
University of California, San Francisco
2016-2025
Neurological Surgery
2016-2025
UCSF Helen Diller Family Comprehensive Cancer Center
2021-2023
University School
2020
Case Western Reserve University
2020
University of Hong Kong
2020
University of California, San Diego
2020
University of California, Los Angeles
2019
University of Rochester Medical Center
2013
Saitama Medical University
2013
Per the World Health Organization 2016 integrative classification, newly diagnosed glioblastomas are separated into isocitrate dehydrogenase gene 1 or 2 (IDH)-wild-type and IDH-mutant subtypes, with median patient survival of 1.2 3.6 years, respectively. Although maximal resection contrast-enhanced (CE) tumor is associated longer survival, prognostic importance within molecular subgroups potential non-contrast-enhanced (NCE) disease poorly understood.To assess association CE NCE tumors in...
PURPOSE In patients with diffuse low-grade glioma (LGG), the extent of surgical tumor resection (EOR) has a controversial role, in part because randomized clinical trial different levels EOR is not feasible. METHODS 20-year retrospective cohort 392 IDH-mutant grade 2 glioma, we analyzed combined effects volumetric and molecular factors on overall survival (OS) progression-free by recursive partitioning analysis. The OS results were validated two external cohorts (n = 365). Propensity score...
We investigated prognostic models based on clinical, radiologic, and radiomic feature to preoperatively identify meningiomas at risk for poor outcomes.Retrospective review was performed 303 patients who underwent resection of 314 (57% World Health Organization grade I, 35% II, 8% III) two independent institutions, which comprised primary external datasets. For each patient in the dataset, 16 radiologic 172 features were extracted from preoperative magnetic resonance images, grade, local...
Diffuse low-grade gliomas include oligodendrogliomas and astrocytomas. The recent 2016 WHO classification has now updated the definition of these tumors to molecular characterization, including presence isocitrate dehydrogenase mutation 1p/19q codeletion. In this new classification, histologic subtype grade II mixed oligoastrocytoma been eliminated. Treatment recommendations are currently evolving, mainly because a change in prognostic factors that based on cytogenetic features. Standard...
"Diffuse midline glioma (DMG), H3 K27M-mutant" is a new tumor entity established in the 2016 WHO classification of Tumors Central Nervous System that comprises set diffuse gliomas arising structures and molecularly defined by K27M mutation genes encoding histone 3 variants H3.3 or H3.1. While this associated with poor prognosis children, clinical experience adults remains limited.Patient demographics, radiologic pathologic characteristics, treatment course, progression, patient survival were...
Chemotherapy improves overall survival after surgery and radiotherapy for newly diagnosed high-risk IDH-mutant low-grade gliomas (LGGs), but a proportion of patients treated with temozolomide (TMZ) will develop recurrent tumors TMZ-induced hypermutation. We aimed to determine the prevalence hypermutation at recurrence prognostic implications.We sequenced from 82 initially who underwent reoperation correlated status grade subsequent clinical outcomes.Hypermutation was associated high-grade...
Abstract Meningiomas are the most common primary intracranial tumors, but molecular drivers of meningioma tumorigenesis poorly understood. We hypothesized that investigating intratumor heterogeneity in meningiomas would elucidate biologic and reveal new targets for therapy. To test this hypothesis, here we perform multiplatform profiling 86 spatially-distinct samples from 13 human meningiomas. Our data regional alterations chromosome structure underlie clonal transcriptomic, epigenomic,...
Abstract Meningiomas are the most common primary intracranial tumors. Treatments for patients with meningiomas limited to surgery and radiotherapy, systemic therapies remain ineffective or experimental. Resistance radiotherapy is in high-grade cell types signaling mechanisms that drive meningioma tumorigenesis resistance incompletely understood. Here, we report NOTCH3 drives find perivascular NOTCH3+ stem cells conserved across from humans, dogs, mice. Integrating single-cell transcriptomics...
A flurry of studies over the past decade has shown that astrocytes play a more active role in neural function than previously recognized. Hippocampal slices prepared from young rodent pups have served as popular model for studying pathways by which participate synaptic transmission. It is, however, not known how well tolerate traumatic injury and hypoxia, are unavoidable when preparing acute slices. We here showed exhibit striking changes expression several receptors structural proteins,...
Abstract “Myxoid glioneuronal tumor, PDGFRA p.K385‐mutant” is a recently described tumor entity of the central nervous system with predilection for origin in septum pellucidum and defining dinucleotide mutation at codon 385 oncogene replacing lysine either leucine or isoleucine (p.K385L/I). Clinical outcomes optimal treatment this new have yet to be defined. Here, we report comprehensive clinical, radiologic, histopathologic assessment eight cases. In addition its stereotypic location...
The FGFR1 gene encoding fibroblast growth factor receptor 1 has emerged as a frequently altered oncogene in the pathogenesis of multiple low-grade neuroepithelial tumor (LGNET) subtypes including pilocytic astrocytoma, dysembryoplastic (DNT), rosette-forming glioneuronal (RGNT), and extraventricular neurocytoma (EVN). These activating alterations LGNET can include tandem duplication exons intracellular tyrosine kinase domain, in-frame fusions most often with TACC1 partner, or hotspot...
BACKGROUNDLong-term prognosis of WHO grade II low-grade gliomas (LGGs) is poor, with a high risk recurrence and malignant transformation into high-grade gliomas. Given the relatively intact immune system patients LGGs slow tumor growth rate, vaccines are an attractive treatment strategy.METHODSWe conducted pilot study to evaluate safety immunological effects vaccination GBM6-AD, lysate allogeneic glioblastoma stem cell line, poly-ICLC in LGGs. Patients were randomized receive before surgery...
Abstract Introduction Tumor Treating Fields (TTFields; antimitotic treatment) delivers low-intensity, intermediate-frequency, alternating electric fields through skin-applied transducer arrays. TTFields (200 kHz) was FDA-approved in glioblastoma (GBM), based on the phase 3 EF-11 (recurrent GBM, rGBM) and EF-14 (newly diagnosed ndGBM) trials. The most common TTFields-related adverse event (AE) both trials array-associated skin irritation. We now report AEs real-world, clinical practice...
BACKGROUND: Increases in the extent of resection both contrast-enhanced (CE) and non–contrast-enhanced (NCE) tissue are associated with substantial survival benefits patients isocitrate dehydrogenase wild-type glioblastoma. The fact, however, remains that these lesions exist within framework complex neural circuitry subserving cognition, movement, behavior, all which affect ultimate outcome. prognostic significance interplay between CE NCE cytoreduction neurological morbidity is poorly...
Abstract Gliomas arising in the setting of neurofibromatosis type 1 (NF1) are heterogeneous, occurring from childhood through adulthood, can be histologically low-grade or high-grade, and follow an indolent aggressive clinical course. Comprehensive profiling genetic alterations beyond NF1 inactivation epigenetic classification these tumors remain limited. Through next-generation sequencing, copy number analysis, DNA methylation gliomas 47 patients, we identified 2 molecular subgroups...
Abstract Glioblastoma is a clinically and molecularly heterogeneous disease, new predictive biomarkers are needed to identify those patients most likely respond specific treatments. Through prospective genomic profiling of 459 consecutive primary treatment-naïve IDH-wildtype glioblastomas in adults, we identified unique subgroup (2%, 9/459) defined by somatic hypermutation DNA replication repair deficiency due biallelic inactivation canonical mismatch gene. The deleterious mutations genes...
Irinotecan demonstrates anti-tumor efficacy in preclinical glioma models but clinical results are modest due to drug delivery limitations. Convection enhanced (CED) improves by increasing intratumoral concentration. Real-time magnetic resonance imaging of infusate during CED may optimize tumor coverage. This phase 1 trial examines the safety and tolerability liposomal irinotecan gadolinium delivered via using real-time MRI guidance recurrent high-grade patients.
Isocitrate dehydrogenase (IDH)-mutant astrocytomas represent the most frequent primary intraparenchymal brain tumor in young adults, which typically arise as low-grade neoplasms that often progress and transform to higher grade despite current therapeutic approaches. However, genetic alterations underlying high-grade transformation disease progression of IDH-mutant remain inadequately defined. Genomic profiling was performed on 205 from 172 patients both initial treatment-naive recurrent...